Clinical trials showed that anti-IL17 and anti-IL23 are more effective for psoriasis than anti-TNFα and ustekinumab, whereas they failed to demonstrate anti-IL17′s superiority vs. anti-TNFα agents for PsA; so anti-TNFα is still considered the mainstay treatment for PsA [45]. The gene discussed is TNF; the disease is psoriasis.